

**S1 Table.** Baseline characteristics of enrolled patients (n=3,176)

<b>Characteristic</b>	<b>No. of patients (%)</b>
<b>Age (yr)</b>	63.84±9.85
≤ 65	1,644 (51.8)
> 65	1,532 (48.2)
<b>Sex</b>	
Male	1,968 (62.0)
Female	1,208 (38.0)
<b>Smoking status</b>	
Never	1,384 (43.6)
Ever	1,778 (56.0)
Unknown	14 (0.4)
<b>ECOG</b>	
0-1	2,589 (81.5)
≥ 2	79 (2.5)
Unknown	508 (16.0)
<b>PFT</b>	
FVC (L)	3.39±1.46
FEV <sub>1</sub> (L)	2.46±0.66
DLco (%)	89.55±20.76
<b>Pathologic T category</b>	
T0	11 (0.3)
T1	1,626 (51.2)
T2	1,242 (39.1)
T3	246 (7.7)
T4	38 (1.2)
Unknown	13 (0.4)
<b>Pathologic N category</b>	
N0	2,444 (77.0)
N1	342 (10.8)
N2	339 (10.7)
N3	5 (0.2)
Unknown	46 (1.4)
<b>Pathologic TNM stage</b>	
I	2,133 (67.2)
II	541 (17.0)
III	410 (12.9)
IV	15 (0.5)
Unknown	77 (2.4)
<b>Histologic type</b>	
Squamous	749 (23.6)
Adenocarcinoma	2,246 (70.7)
Large cell carcinoma	46 (1.4)
NSCLC, NOS	17 (0.5)
Adenosquamous	36 (1.1)
Carcinoid	30 (0.9)
Others	52 (1.6)
<b>Pleural invasion</b>	
None (PL0)	2,397 (75.5)
Visceral pleural invasion (PL1)	533 (16.8)
Invasion to the surface of the visceral pleura (PL2)	128 (4.0)
Extend to the parietal pleura (PL3)	78 (2.5)
Pleural invasion, NOS	18 (0.6)

Unknown	22 (0.7)
<b>EGFR</b>	
Positive	867 (27.3)
Negative	1,266 (39.9)
Unknown	1,043 (32.8)
<b>ALK</b>	
Positive	115 (3.6)
Negative	1,923 (60.5)
Unknown	1,138 (35.8)
<b>Recurrence</b>	
No recur	2,631 (82.8)
Late recur	328 (10.3)
Early recur ( $\leq 1$ yr)	217 (6.8)
<b>Death</b>	
No	2,515 (79.2)
Yes	661 (20.8)
<b>Observation time (mo)</b>	35.41 $\pm$ 13.55
<b>Recurrence-free survival time (mo)</b>	31.73 $\pm$ 14.60

---

Values are presented as mean $\pm$ SD or number (%). ALK, anaplastic lymphoma kinase; ALK positive, ALK immunohistochemistry or fluorescence *in situ* hybridization positive; DLco, diffusing capacity of the lungs for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; FEV<sub>1</sub>, forced expiratory volume exhaled in the first second; FVC, forced vital capacity; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PFT, pulmonary function test; RT, radiotherapy; SD, standard deviation.